What are the recommendations for women who become pregnant while taking Mounjaro (tirzepatide)?

Recommendations for Women Who Become Pregnant While Taking Mounjaro (Tirzepatide)

Women who become pregnant while taking Mounjaro (tirzepatide) should discontinue the medication immediately due to insufficient safety data in pregnancy and potential fetal risks.

Evidence on Tirzepatide Use in Pregnancy

The FDA label for Mounjaro (tirzepatide) provides clear guidance regarding use during pregnancy 1:

• Available data on tirzepatide use in pregnant women are insufficient to evaluate drug-related risks of major birth defects, miscarriage, or other adverse maternal or fetal outcomes
• Animal reproduction studies showed potential risks to the fetus:
  • In pregnant rats, fetal growth reductions and fetal abnormalities occurred at clinical exposure levels
  • In pregnant rabbits, fetal growth reductions were observed at clinically relevant exposures
  • These adverse embryo/fetal effects coincided with effects on maternal weight and food consumption

Management Algorithm for Women Who Conceive While Taking Mounjaro

Immediate Actions

1. Stop Mounjaro immediately upon confirmation of pregnancy
2. Schedule prompt obstetric consultation for pregnancy risk assessment
3. Document pregnancy in manufacturer's pregnancy registry if available

Follow-up Care

1. Monitor for hyperglycemia if tirzepatide was prescribed for diabetes management

   • Consider alternative diabetes treatments that are pregnancy-compatible
   • Insulin is generally the preferred treatment for diabetes during pregnancy

2. Fetal assessment

   • Consider detailed anatomical ultrasound to assess fetal development
   • Monitor fetal growth throughout pregnancy

Contraception Recommendations

For women of childbearing potential taking Mounjaro who are not seeking pregnancy:

• Use effective contraception while on tirzepatide
• The FDA label specifically notes: "Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation with MOUNJARO" 1
• This recommendation is due to tirzepatide's effect on delaying gastric emptying, which may impact the absorption of oral contraceptives

Preconception Planning

For women taking Mounjaro who wish to become pregnant:

1. Discontinue tirzepatide before attempting conception
2. Establish alternative management strategies for the condition being treated
3. Consider washout period before conception attempts (though specific duration is not established in guidelines)

Important Caveats

• There are currently no published case studies or clinical trials specifically addressing tirzepatide use in pregnancy
• The FDA pregnancy category information indicates potential risk based on animal studies
• The recommendation to discontinue is based on the precautionary principle and lack of human safety data
• This guidance aligns with the general approach to medications with limited pregnancy safety data, similar to recommendations for other newer diabetes and weight management medications

Alternative Management Options

If tirzepatide was prescribed for:

1. Type 2 diabetes: Consider insulin therapy, which has established safety in pregnancy
2. Weight management: Focus on dietary and lifestyle modifications appropriate for pregnancy